U
Acura Pharmaceuticals, Inc. ACUR
$0.05 $0.000.00%
Recommendation
--
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
D
Sell 11/11/2022Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D- from D on 11/11/2022 due to a significant decline in the valuation index.
D
Sell 10/27/2022Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D from D- on 10/27/2022 due to a significant increase in the valuation index and volatility index.
D
Sell 9/30/2022Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D- from D on 9/30/2022 due to a significant decline in the total return index and volatility index.
D
Sell 5/5/2022Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell 4/20/2022Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell 11/17/2021Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D from D- on 11/17/2021 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 198.45% from -$194 to $191, and earnings per share increased from -$0.01 to -$0.0035.
D
Sell 11/8/2021Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the valuation index.
D
Sell 11/17/2020Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D from C- on 11/17/2020 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.0095 to -$0.021, net income declined 320.13% from $308 to -$678, and EBIT declined 234.2% from $421 to -$565.
C
Hold 8/18/2020Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to C- from D on 8/18/2020 due to a significant increase in the efficiency index, growth index and total return index. Net income increased 151.76% from -$595 to $308, earnings per share increased from -$0.02 to $0.0095, and EBIT increased 127.57% from $185 to $421.
D
Sell 3/17/2020Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D from D+ on 3/17/2020 due to a decline in the volatility index and total return index.
D
Sell 2/28/2020Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D+ from D on 2/28/2020 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 2,778.26% from $46 to $1.32M, the quick ratio increased from 0.08 to 0.66, and EBIT increased 150% from -$622 to $311.
D
Sell 10/11/2019Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D from D- on 10/11/2019 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 67.38% from -$1.22M to -$399, and total revenue increased 6.35% from $63 to $67.
D
Sell 9/12/2019Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D- from D on 9/12/2019 due to a decline in the volatility index.
D
Sell 8/27/2019Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D from D- on 8/27/2019 due to a large increase in the efficiency index, total return index and volatility index. Net income increased 13.16% from -$1.26M to -$1.1M.
D
Sell 6/8/2018Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D- from E+ on 6/8/2018 due to an increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 2.26 to -99.78, and net income increased 21% from -$2.2M to -$1.74M.
E
Sell 4/30/2018Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to E+ from D- on 4/30/2018 due to a decline in the volatility index.
D
Sell 2/21/2018Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D- from E+ on 2/21/2018 due to an increase in the volatility index and total return index.
E
Sell 11/15/2017Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to E+ from D- on 11/15/2017 due to a decline in the valuation index, solvency index and efficiency index. Debt to equity increased from -13.4 to 2.26, and net income declined 2.37% from -$2.15M to -$2.2M.
D
Sell 5/12/2017Upgraded
Acura Pharmaceuticals, Inc. (ACUR) was upgraded to D- from E+ on 5/12/2017 due to an increase in the growth index, valuation index and solvency index. Debt to equity declined from 4.53 to 2.88, and the quick ratio increased from 0.81 to 0.89.
E
Sell 3/31/2017Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to E+ from D- on 3/31/2017 due to a major decline in the growth index, solvency index and valuation index. Debt to equity increased from -12.66 to 4.53, and the quick ratio declined from 1.06 to 0.81.
D
Sell 3/11/2016Downgrade
Acura Pharmaceuticals, Inc. (ACUR) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, total return index and efficiency index. Total capital declined 9.19% from $17.23M to $15.65M.
Weiss Ratings